Search

Displaying results 2211 - 2220 of 8412 in total
  1. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  2. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  3. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942] … In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). … [L46108] Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.

    Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP
  5. Drug

    Growth hormone-releasing peptide 1

    go.drugbank.com/drugs/DB19259
    Investigational

    investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG

    Synonyms: Ala-his-3-(2-naphthalenyl)-d-ala-ala-trp-d-phe-lys-nh2, L-alanyl-l-histidyl-3-(2-naphthalenyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide
  6. Indication

    Osteoporosis

    go.drugbank.com/conditions/DBCOND0015928
    Drugs: Abaloparatide · Alendronic acid · Boron · Calcium · Calcium carbonate · Calcium citrate +20 more
  7. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  8. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) [A256778] and an agonist at the parathyroid hormone type 1 (PTH1) receptor. … [A256778] Abaloparatide is an osteoanabolic agent that stimulates bone formation.

  9. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  10. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates